Application of Piezo1 agonist in preparation of medicine for treating Marfan syndrome

By using Piezo1 agonist Yoda1 to activate the Piezo1 channel and inhibit the TGF-β signaling pathway, the problem of insufficient effective intervention targets in the treatment of aneurysms in Marfan syndrome is solved, and effective inhibition of aneurysms and degree of vascular autophagy is achieved. Improvement provides a new treatment plan.

CN119055770APending Publication Date: 2024-12-03THE CENTRAL HOSPITAL OF WUHAN (WUHAN NO 2 HOSPITAL WUHAN CANCER RESEARCH INSTITUTE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411014646.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing drug treatment plans lack effective intervention targets for aortic aneurysms in Marfan syndrome, and cannot effectively prevent and inhibit the formation and rupture of aneurysms. Blood pressure control is particularly important in patients with cardiovascular risk, but there is a lack of new treatments. plan.

Method used

By using substances such as Piezo1 agonist Yoda1, Piezo1 channel is activated, TGF-β signaling pathway is inhibited, collagen and metal matrix protease-related proteins are reduced, vascular dilation is reduced, and the degree of vascular autophagy is increased, thereby inhibiting the development of aneurysms.

Benefits of technology

The Piezo1 agonist Yoda1 can effectively inhibit the activation of the TGF-β signaling pathway, reduce the vasodilation of aneurysms, improve the pathological changes of aortic aneurysms, and provide a new drug target for the treatment of Marfan syndrome aneurysms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055770A_ABST
    Figure CN119055770A_ABST
Patent Text Reader

Abstract

The invention provides an application of a Piezo1 agonist or pharmaceutically acceptable salt and ester thereof in preparation of a medicine for treating horse's syndrome, an application of a Piezo1 gene or protein in preparation of a medicine for treating horse's syndrome, and a corresponding pharmaceutical composition. Particularly, the Piezo1 agonist is selected from a substance capable of improving the Piezo1 protein activity or up-regulating the Piezo1 gene expression level, and the Piezo1 agonist is selected from Yoda1, Jed1, Jed2 or Yaddle1.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and relates to the use of a Piezo1 agonist in preparing a drug for treating Marfan syndrome and a pharmaceutical composition for treating Marfan syndrome, and particularly relates to the use of a Piezo1 agonist Yoda1 in preparing a drug for treating aortic aneurysm caused by Marfan syndrome. Background Art

[0002] Marfan syndrome (MFS) is an autosomal dominant connective tissue disease, mainly caused by mutations in the FBN1 gene, with an incidence rate of about 6.5 / 10,000. MFS is mainly manifested in the musculoskeletal system (thin and long fingers, peculiar bones) and cardiovascular system (cardiovascular system involvement is the most dangerous lesion, most patients are accompanied by congenital vascular malformations, common aortic dilatation and heart valve insufficiency, and may be combined with various arrhythmias, such as conduction block, atrial flutter, atrial fibrillation, etc., patients have aneurysmal dilatation of the ascending aorta, prone to aortic aneurysm rupture and bleeding, which can cause sudden death in severe cases. This is acute and is the main cause of death). There may also be other abnormalities, such as slender teeth, poor development of secondary sexual characteristics, pulmonary lobes, wandering kidneys, ureteral stenosis and other abnormalities. The main hazard of MFS is cardiovascular disease, especially the formation of aortic aneurysms. Thoracic aortic aneurysm (TAA) is its important cardiovascular manifestation, specifically the aneurysmal dilatation of the aortic root or ascending aorta, which is seriously life-threatening once ruptured. Due to the large trauma of surgical treatment, the existing drug treatment programs mainly focus on lowering blood pressure and heart rate, and there is a lack of effective drug treatment programs. Therefore, it is of great clinical significance to find effective intervention targets in MFS ascending aortic aneurysms, prevent them as early as possible, and curb the formation and rupture of aneurysms.

[0003] Overactivation of the transforming growth factor (TGF-β) signaling pathway is currently considered to be the main pathogenic mechanism of MFS arterial dilatation. Previous studies have shown that inhibition of this pathway can have a therapeutic effect on aneurysms. For example, administration of pan-TGF-β neutralizing antibodies to MFS animal model mice can antagonize the hyperphosphorylation of Smad2 protein and inhibit the formation of aneurysms. Inhibition of JNK and ERK1 / 2 protein activation can also reduce arterial lesions. At the same time, clinical treatment guidelines recommend that blood pressure control is particularly important in patients at risk of Marfan syndrome aneurysms. Therefore, finding molecular targets that can inhibit the TGF-β signaling pathway and improve blood pressure is the key to solving Marfan syndrome aneurysms.

[0004] Patent US20230203584A1 discloses a method for assessing a subject's risk of having an ascending thoracic aortic aneurysm or a descending thoracic aortic aneurysm by detecting one or more single nucleotide polymorphisms (SNPs) in one or more specific genes, and also discloses a method for calculating a polygenic score to assess a subject's risk, which can be used to identify asymptomatic subjects at risk of aneurysms. The patent also discloses treatment of subjects with ascending thoracic aortic aneurysms or descending thoracic aortic aneurysms by drugs, surgery, or both, wherein the drugs include aspirin, antihypertensive drugs, and statins. The above patent is used to assess a subject's risk of having a thoracic aortic aneurysm, and no new solutions for further studying the symptoms of thoracic aortic aneurysms have been developed.

[0005] The Piezo1 molecule is an important mechanosensitive ion channel protein on the cell membrane. It is involved in regulating many physiological and pathological stress responses and controlling the entry of various cations such as calcium, potassium, and magnesium into cells. Literature 1 (Zeng WZ, Marshall KL, Min S, Daou I, Chapleau MW, Abboud FM, Liberles SD, Patapoutian A. PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex. Science. 2018 Oct 26; 362(6413): 464-467. doi: 10.1126 / science.aau6324. PMID: 30361375; PMCID: PMC6563913.) reported that the mechanosensitive ion channel proteins Piezo1 and Piezo2 act as pressure receptors that effectively regulate acute blood pressure. Double knockout of Piezo1 and Piezo2 in the colon-oculum-jugular complex of mice can completely eliminate aortic inhibitory nerve activity and drug-induced pressure reflexes. Reference 2 (Tang H, Zeng R, He E, Zhang I, Ding C, Zhang A. Piezo-Type Mechanosensitive Ion Channel Component 1 (Piezo1): A Promising Therapeutic Target and Its Modulators. J MedChem. 2022 May 12; 65 (9): 6441-6453. doi: 10.1021 / acs.jmedchem.2c00085. Epub 2022 April 24. PMID: 35466678.) reported that Piezo1 plays a complex and important role in vascular remodeling, endothelial inflammation, acute blood pressure regulation, red blood cell volume balance, and lymphatic vessel development, and may become a new therapeutic target for the treatment of circulatory system diseases (such as atherosclerosis and hypertension). The above references 1 and 2 suggest that Piezo1 may be related to cardiovascular disease, but no further exploration of the thoracic aortic aneurysm-related diseases in Marfan syndrome was conducted. Piezo1 is involved in regulating multiple physiological functions of the circulatory system, including vascular development, angiogenesis and remodeling, blood pressure regulation and myocardial contraction. The Piezo1 molecule is very likely to become an effective target for the treatment of Marfan syndrome aneurysms. Summary of the invention

[0006] Based on previous research, the inventors further explored the role of Piezo1 molecules in Marfan syndrome aneurysm disease and found that the expression of Piezo1 molecules was abnormally reduced in MFS aneurysms. Piezo1 molecules play a protective role in the occurrence and development of aneurysms, and their downregulation can lead to the deterioration of the disease. In vitro treatment of smooth muscle cells with the Piezo1 molecule-specific agonist Yoda1 resulted in inhibition of the activation of the TGF-β signaling pathway and decreased expression of collagen and matrix metalloproteinase-related proteins. Injection of Yoda1 into model mice reduced vascular dilation of MFS aneurysms, reduced vascular wall thickness, reduced extracellular matrix remodeling, and weakened elastic fiber rupture. Yoda1 increased the degree of vascular autophagy and improved aneurysm dilation.

[0007] In view of this, the present application first proposes the following pharmaceutical application technical solution:

[0008] Use of a Piezo1 agonist or a pharmaceutically acceptable salt or ester thereof in preparing a drug for treating Marfan syndrome.

[0009] Use of Piezo1 gene or protein in preparing medicine for treating Marfan syndrome.

[0010] As a preferred embodiment of the present application, the above-mentioned Piezo1 agonist is selected from substances that can increase the activity of Piezo1 protein or upregulate the expression level of Piezo1 gene.

[0011] As a preferred embodiment of the present application, the above-mentioned Piezo1 agonist is selected from Yoda 1, Jedi1, Jedi2 or Yaddle1.

[0012] Yoda1 activates purified Piezo1 channels, which enhances Ca 2+ Influx, a potent and selective Piezo1 agonist, has the following structural formula:

[0013]

[0014] Jedi2 causes Piezo1-mediated Ca 2+ Influx, Jedi2 (200 μM) specifically triggered a dose-dependent response in mPiezo1-transfected cells. Co-administration of Jedi1 and Yoda1 resulted in a synergistic activation of Piezo1, suggesting that the two agonists may activate Piezo1 through different binding sites. Jedi1 and Jedi2 share a common furan-3-carboxylic acid group, suggesting that this structural group may be responsible for the activation of Piezo1 channels. Structural formulas and related K values ​​of Jedi1 and Jedi2 d ,EC 50 The data looks like this:

[0015]

[0016] Yaddle1 is a Piezo1 agonist that induces human CD4 + The structural formula of calcium influx in T cells is as follows:

[0017]

[0018] As a preferred embodiment of the present application, the above-mentioned Marfan syndrome is manifested as thoracic aortic aneurysm, which is manifested as aneurysmal dilatation of the aortic root or ascending aorta. The cardiovascular lesions in MFS are mainly characterized by the formation of thoracic aortic aneurysms. The formation of thoracic aortic aneurysms and subsequent rupture of the aneurysms are the main causes of death in patients.

[0019] As a preferred embodiment of the present application, the above-mentioned drug for treating Marfan syndrome can be achieved by inhibiting the TGF-β signaling pathway.

[0020] Some people believe that the main cause of thoracic aortic aneurysm is the FBN1 gene mutation, which leads to a decrease in the synthesis quality of fibrinogen-1, making it impossible for microfibrils to bind to the large latent complex (LLC), resulting in the failure of transforming growth factor-β (TGF-β) to chelate with it, causing an increase in plasma TGF-β levels, thereby promoting excessive activation of the TGF-β signaling pathway, increasing collagen production, reducing aortic compliance, and upregulating the levels of elastase and matrix metalloproteinases (MMPs), leading to elastic fiber degradation.

[0021] The study in this application shows that Piezo1 gene knockout will aggravate the abnormal activation of the TGF-β signaling pathway (increased phosphorylation of SMAD2 and ERK1 / 2), thereby causing an increase in the expression of the metal matrix proteinase family (MMP2, MMP9), destroying and remodeling the extracellular matrix, and aggravating aneurysms. In addition, after the aortic aneurysm vessels of mice were treated with Yoda1, protein immunoblotting found that the content of the TGF-β signaling pathway receptor TGFBR1 protein on the cell membrane and cytoplasm did not change significantly, while the content of the receptor TGFBR2 protein in the cell membrane was significantly reduced, and the content in the cytoplasm was significantly increased. At the same time, immunofluorescence confocal captures the transfer process of the TGFBR2 receptor from the cell membrane to the cytoplasm.

[0022] As a preferred embodiment of the present application, the above-mentioned inhibition of TGF-β signaling pathway can be achieved by inhibiting the expression of TGFBR2 protein on the cell membrane or transferring TGFBR2 protein from the cell membrane to the cytoplasm.

[0023] The present application also provides the following pharmaceutical composition:

[0024] A pharmaceutical composition for treating Marfan syndrome, comprising at least one of a Piezo1 agonist, a Piezo1 protein or a TGF-β inhibitor.

[0025] As a preferred embodiment of the present application, in the pharmaceutical composition for treating Marfan syndrome, the Piezo1 agonist is selected from substances that can increase the activity of Piezo1 protein or upregulate the expression level of Piezo1 gene.

[0026] As a preferred embodiment of the present application, in the pharmaceutical composition for treating Marfan syndrome, the Piezo1 agonist is selected from Yoda 1, Jedi1, Jedi2 or Yaddle1.

[0027] As a preferred embodiment of the present application, in the pharmaceutical composition for treating Marfan syndrome, the Marfan syndrome is manifested as thoracic aortic aneurysm, and the thoracic aortic aneurysm is manifested as a tumor-like dilatation of the aortic root or ascending aorta.

[0028] This application studies the expression changes of Piezo1 molecules in Marfan syndrome aneurysm disease, the in vitro and in vivo effects of Piezo1 molecules in Marfan syndrome aneurysm disease, the effects and mechanisms of Piezo1 molecule agonists on the TGF-β signaling pathway, and the effects of agonist drugs in Marfan syndrome aneurysm model mice. It is found that:

[0029] 1. The expression of PIEZO1 molecule is abnormally reduced in MFS aneurysms, suggesting that PIEZO1 molecule may be an effective target for its drug treatment.

[0030] 2. In all segments of the aorta of MFS model mice, PIEZO1 molecules were abnormally downregulated; in vascular samples of MFS patients, PIEZO1 molecules were also abnormally downregulated.

[0031] 3. The Piezo1 gene was knocked out in disease model mice, and they showed severe thoracic aortic aneurysm after natural growth to 14 weeks of age. Compared with their controls, the aortic dilation was more severe and occurred earlier.

[0032] 4. Piezo1 gene deletion leads to increased vascular wall thickness, extracellular matrix disorder, conversion of vascular smooth muscle cell phenotype from contractile to synthetic secretory, and increased thinning and breakage of elastic fibers, further confirming the aggravation of aneurysms.

[0033] 5. Piezo1 gene deletion leads to increased cell apoptosis, aggravated extracellular matrix remodeling, and upregulated expression of collagen and metal matrix proteinase family.

[0034] 6. Piezo1 gene knockout will aggravate the abnormal activation of the TGF-β signaling pathway, thereby causing the increased expression of the metal matrix proteinase family, destroying and remodeling the extracellular matrix, and aggravating aneurysms.

[0035] 7. The PIEZO1 molecule plays a protective role in the occurrence and development of aneurysms, and its downregulation can lead to the deterioration of the disease, indicating that intervention in this molecule may be an effective measure to treat MFS aneurysms.

[0036] 8. Smooth muscle cells were treated in vitro with Yoda1, a Piezo1-specific agonist. Immunoblotting and fluorescence experiments showed that the activation of the TGF-β signaling pathway was inhibited, and the expression of collagen and matrix metalloproteinase-related proteins was decreased. Yoda1 may be used as a therapeutic agent for aneurysms. After Yoda1 stimulation, extracellular matrix remodeling, angiotensin pathway, apoptosis pathway and other pathways were all decreased, indicating that Yoda1 played an inhibitory effect on the development of aneurysms, while also having a lowering effect on blood pressure and a protective effect on smooth muscle apoptosis.

[0037] 9. The receptors of the TGF-β signaling pathway on the cell membrane were detected. The expression of type 1 receptor (TGFBR1) did not change under Yoda1 stimulation, while the expression of type 2 receptor (TGFBR2) decreased under Yoda1 stimulation and the expression in the cytoplasm increased. At the same time, immunofluorescence confocal microscopy captured the transfer process of type 2 receptor from the cell membrane to the cytoplasm. The reduced expression of the receptor on the cell membrane led to the inhibition of the activation of the TGF-β signaling pathway.

[0038] 10. Intraperitoneal injection of Yoda1 in MFS model mice reduced the vascular dilation of MFS aneurysms. Pathological staining showed that the thickness of the vascular wall was reduced, the remodeling of the extracellular matrix was reduced, and the rupture of elastic fibers was weakened. The activation of the TGF-β signaling pathway and the proteins related to extracellular matrix remodeling were reduced, and the dilation of MFS aneurysms was inhibited. Yoda1 increased the degree of vascular autophagy and improved the dilation of aneurysms.

[0039] In addition to containing the corresponding main pharmacodynamic substances, the medicine or pharmaceutical composition described in this application should also add pharmaceutically acceptable adjuvants or excipients according to the characteristics of medicines, drugs, and preparations. The medicine or pharmaceutical composition can be any dosage form for clinical use, such as tablets, suppositories, dispersible tablets, enteric-coated tablets, chewable tablets, orodisintegrating tablets, capsules, sugar-coated tablets, granules, dry powders, oral solutions, small needles for injection, freeze-dried powder for injection or large infusions. According to specific dosage forms and modes of administration, the pharmaceutically acceptable adjuvants or excipients in the medicine or pharmaceutical composition can include one or more of the following: diluents, solubilizers, disintegrants, suspending agents, lubricants, adhesives, fillers, flavoring agents, sweeteners, antioxidants, surfactants, preservatives, wrappers, and pigments, etc.

[0040] For any terms not specifically explained or described in this application text, please refer to the textbooks on medicinal chemistry, organic chemistry, biochemistry, pharmacology or food and beverage related. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 Venn diagram for genetic screening;

[0042] Figure 2 The bar graphs are the expression of Piezo1 and Icam1 genes in aorta samples of wild-type mice and Marfan syndrome model mice, where the left picture is the expression bar graph of Piezo1 gene, and the right picture is the expression bar graph of Icam1 gene;

[0043] Figure 3 The results of WB detection of Piezo1 protein in ascending aorta blood vessel samples of wild-type mice (WT) and Marfan syndrome model mice (MFS). The left picture is a photo of protein bands detected by WB, and the right picture is a bar graph of the ratio of Piezo1 protein to the internal reference protein β-actin;

[0044] Figure 4 The results of immunohistochemical staining of Piezo1 protein in the ascending aorta, descending aorta, and abdominal aorta of wild-type mice and Marfan syndrome model mice are shown in the figure on the left, and the figure on the right is a bar graph showing the percentage of Piezo1 protein staining area. In each group of bar graphs, the left side shows wild-type (WT) mice, and the right side shows Marfan syndrome model (MFS) mice.

[0045] Figure 5 The results of WB detection of Piezo1 protein in blood vessel samples of healthy subjects (Donor) and patients with Marfan syndrome (MFS). The left picture is a photo of protein bands detected by WB, and the right picture is a bar graph of the ratio of Piezo1 protein to the internal reference protein β-actin;

[0046] Figure 6 The immunohistochemical staining results of Piezo1 protein in blood vessel samples of healthy subjects (Donor) and patients with Marfan syndrome (MFS), where the left picture is a photo of immunohistochemical staining and the right picture is a bar chart of the percentage of Piezo1 protein staining area;

[0047] Figure 7 Schematic diagram of the construction of Piezo1 knockout mice;

[0048] Figure 8The photos are of aortic aneurysm growth in mice of the control group (CON), conditional knockout group (CKO), Marfan syndrome model group (MFS), and Marfan syndrome superimposed conditional knockout group (MFS x CKO). The upper photo is the anatomical diagram of mice in each group, and the lower photo is the ultrasound detection photo of mice in each group.

[0049] Fig. 9 Diameter bar graphs of the ascending aorta (Asc), arch aorta (Arch), and descending aorta (Desc) of mice in the CON group, CKO group, MFS group, and MFS x CKO group. In each group of bar graphs, from left to right are the CON group, CKO group, CKO group, and MFSx CKO group.

[0050] Fig.10 HE staining and EVG staining images of aorta vessels of mice in CON group, CKO group, MFS group, and MFS x CKO group, as well as the corresponding bar graphs of elastic fiber breaks (Elastinbreaks);

[0051] Fig.11 The pictures of signal pathway changes in aortic vascular cells mRNA transcriptome sequencing of CON group, CKO group, MFS group, and MFS x CKO group model mice, among which the left picture is apoptosis, the middle picture is collagen containing extracellular matrix, and the right picture is extracellular matrix disassembly.

[0052] Fig.12 This is the gene expression heat map of mRNA transcriptome sequencing of aortic vascular cells in the CON group, CKO group, MFS group, and MFS x CKO group of mice;

[0053] Fig.13 The immunofluorescence staining results of MMP2, MMP9 and p-SMAD2 proteins in the aorta of mice in the CON group, CKO group, MFS group and MFS x CKO group are shown in the figure above. The figure below is a bar graph showing the percentage of the immunofluorescence positive area of ​​each protein. The bar graphs of each protein are CON group, CKO group, CKO group and MFS x CKO group from left to right.

[0054] Fig.14 The immunoblot photos of various proteins in the aorta of mice in the CON group, CKO group, MFS group, and MFS x CKO group;

[0055] Fig.15 The left picture is the immunoblot picture of FN1, COL1A1, MMP9, and MMP2 proteins in MFS smooth muscle cells (VSMCs) treated with or without Yoda1, and the right picture is the immunoblot picture of TGF-β1 pathway marker proteins in the case of Yoda1 addition or not, and ACTIN is the internal reference protein;

[0056] Fig.16 Immunofluorescence staining images of p-SMAD2 and p-ERK1 / 2 proteins with or without the addition of Yoda1;

[0057] Fig.17 The following are the changes in signal pathways of mRNA transcriptome sequencing of aortic vascular cells in MFS model mice under the stimulation of Yoda1 or not. The upper left picture shows the Renin Angiotensin System, the upper right picture shows the negative regulation of apoptotic signaling pathway, the lower left picture shows the collagen containing extracellular matrix, and the lower right picture shows the cell adhesion via cell membrane adhesion molecules.

[0058] Fig.18 This is the gene expression heat map of mRNA transcriptome sequencing of aortic vascular cells in MFS model mice under Yoda1 stimulation or not;

[0059] Fig.19 The immunoblot images are of TGF-β signaling pathway receptors TGFBR1 and TGFBR2 proteins in the membrane and cytosol of cells treated with or without Yoda1.

[0060] Fig. 20 Immunofluorescence confocal images of TGFBR2 protein treated with or without Yoda1;

[0061] Fig.21 The photos are of aortic aneurysm growth in wild-type mice (WT), MFS model mice (MFS+Vehicle), and MFS intraperitoneally injected Yoda1 model mice (MFS+Yoda1). The upper photo is the anatomical diagram of each group of mice, and the lower photo is the ultrasound detection photo of each group of mice.

[0062] Fig. 22Diameter bar graphs of the ascending aorta (Asc), arch aorta (Arch), and descending aorta (Desc) of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group. In each group of bar graphs, from left to right are the WT group, MFS+Vehicle group, and MFS+Yoda1 group.

[0063] Fig.23 HE staining and EVG staining images of aorta vessels of mice in WT group, MFS+Vehicle group, and MFS+Yoda1 group, as well as the corresponding bar graphs of elastic fiber breaks (Elastinbreaks);

[0064] Fig.24 The immunofluorescence staining results of MMP2, COL1A1, p-SMAD2, and p-ERK1 / 2 proteins in the aorta of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group are shown, where the left figure is a photo of immunofluorescence staining of each protein, and the right figure is a bar graph showing the percentage of the immunofluorescence positive area of ​​each protein;

[0065] Fig.25 These are the pictures of protein immunoblotting detection of MMP2, MMP9, p-SMAD2, SMAD2, p-ERK1 / 2, and ERK1 / 2 in the aorta of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group;

[0066] Fig.26 These are the pictures of immunoblotting detection of SQSTM1, LC3-I, and LC3-II proteins in the aorta of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group;

[0067] Fig. 27 The immunoblot detection images of TGFBR2 protein in the aortic vascular cell membrane (Membrane) of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group;

[0068] Fig.28 These are the results of immunohistochemical staining of SQSTM1 protein in the aorta of mice in the WT group, MFS+Vehicle group, and MFS+Yoda1 group. The left figure is an immunohistochemical staining picture, and the right figure is a bar graph showing the percentage of the positive area of ​​SQSTM1 protein immunohistochemical staining. DETAILED DESCRIPTION

[0069] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0070] The experimental methods in the following examples all comply with laboratory and ethical requirements, and are conventional methods unless otherwise specified. The experimental raw materials, reagent materials, strains, detection kits, etc. used in the following examples are all commercially available products unless otherwise specified.

[0071] Example 1 Screening of Piezo1 molecular targets and identification of expression levels in diseases

[0072] The "mouse model of hypertension" and "mouse model of thoracic aortic aneurysm disease" were searched in the GEO database, and the GSE205267 and GSE241968 data sets were selected respectively. GSEA enrichment analysis was performed in R language, focusing on the down-regulated enriched pathways, and the related genes in the same pathways enriched in the two disease data were intersected to obtain the two target molecules, Piezo1 and Icam1. qRT-PCR verification confirmed that the expression of the Piezo1 molecular target had a decreased change in MFS disease.

[0073] Page 10 of 30

[0074] The specific experimental methods and experimental results are as follows.

[0075] Bioinformatics analysis:

[0076] Log in to the US NCBI GEO database (https: / / www.ncbi.nlm.nih.gov / geo / ) and search for "Mouse model of hypertension" and "Mouse model of thoracic aortic aneurysm disease". Select the GSE205267 and GSE241968 transcriptome sequencing data sets, download the gene sequencing expression matrix, and read it into the R language. Select the limma package to perform differential gene analysis between the disease group and the control group, and use the ggplot2 package to draw a gene expression heat map. A total of 22,768 differential genes were obtained in the "Mouse model of hypertension" data set, and a total of 26,415 differential genes were obtained in the "Mouse model of thoracic aortic aneurysm disease" data set. Perform GSEA or GSVA enrichment analysis using differential genes as input files. Focus on the common down-regulated pathways in the two data sets, involving a total of 3 pathways, namely: cell adhesion regulation, extracellular stimulus response, and protein complex aggregation regulation. Take the intersection of the related genes involved in the common pathways to obtain two candidate genes: Piezo1 and Icam1, such as Figure 1 Venn diagram shown.

[0077] Mouse aorta blood vessel sample acquisition:

[0078] A. 3% sodium pentobarbital at 0.2 ml / kg was intraperitoneally injected to anesthetize mice.

[0079] B. After the animal's limbs are obviously relaxed and its response to stimulation is weakened, transfer it to the operating table.

[0080] C. The animal is placed in a supine position with its limbs fixed, and disinfected with 75% alcohol. The skin is incised in the middle of the abdomen, and then the sternum is cut upward to expose the chest cavity.

[0081] D. Use forceps and cotton swabs to push aside other organ tissues to expose the entire aorta, and use forceps to free the aorta.

[0082] E. The proximal end is cut from the aortic root, and the distal end is cut from the renal bifurcation of the abdominal aorta. Transfer the entire aorta to a glass dish and rinse the blood stains with saline.

[0083] F. Freeze the specimen in a -80℃ refrigerator or immerse it in tissue fixative for subsequent experiments.

[0084] qRT-PCR detection:

[0085] Mice were divided into control wild-type mice and Marfan syndrome model mice, and aortic blood vessel samples were obtained as described above. Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse transcribed into complementary DNA (cDNA) using HiScript IIQ RT SuperMix for qPCR (Vazyme). qRT-PCR was performed using the SYBR Green PCR kit (Vazyme) on the ABI StepOne Plus detection system (Applied Biosystems).

[0086] GAPDH was used as an endogenous control.

[0087] The primer sequences are as follows:

[0088] Piezo1:F-5'-TCATCATCCTTAACCACATGGTG-3'

[0089] R-5'-TGAAGACGATAGCTGTCATCCA-3';

[0090] Icam1:F-5'-AGATCACATTCACGGTGCTGGCTA-3'

[0091] R-5'-GCTTTGGGATGGTAGCTGGAAGA-3';

[0092] Gapdh: F-5'-CTCATGACCACAGTCCATGC-3'R-5'-CACATTGGGGGTAGGAACAC-3'.

[0093] The experimental results are as follows Figure 2 As shown in the figure, the expression of Piezo1 gene in the aorta samples of Marfan syndrome model mice was significantly lower than that of wild-type mice, with a P value of 0.0002, which was significant; while there was no significant difference in the expression of Icam1 gene in Marfan syndrome model mice and wild-type mice. The experimental results showed that the expression of Piezo1 molecule in the aorta of Marfan syndrome was significantly reduced.

[0094] Example 2 Western blotting and immunohistochemistry of Piezo1 molecules in the ascending aorta, descending aorta, abdominal aorta segments of mice and blood vessel samples of MFS patients Western blotting protein immunoblotting detection:

[0095] A. Clean and dry the glass plate.

[0096] B. A 10% protein polyacrylamide gel was prepared using a rapid gel preparation kit (YaZyme).

[0097] C. The mouse aorta samples obtained by the above method were lysed with 200 μl RIPA lysis buffer (biosharp), and after adding loading buffer (biosharp), they were placed in a metal bath at 100 degrees Celsius for 15 minutes to obtain the protein loaded by western blot.

[0098] D. Place the gel in the electrophoresis tank, add electrophoresis solution, and then add the samples to be tested. Perform electrophoresis at a constant voltage of 200V for 20 minutes.

[0099] E. Cut the filter paper and PVDF membrane into appropriate sizes, and place the negative electrode of the transfer clamp with sponge, filter paper, PVDF membrane, gel, filter paper, and sponge in sequence.

[0100] F. Transfer the splint to the tank, add 1L of transfer solution, and transfer the membrane at a constant current of 400mA for 40 minutes.

[0101] G. Remove the PVDF membrane, block and wash it, transfer it to the antibody solution, and incubate it at 4°C overnight.

[0102] H. Remove the PVDF membrane, wash it, and incubate it with secondary antibody (Seville) at room temperature for 1 hour.

[0103] I. Wash the PVDF membrane and use ECL exposure solution (Seville) to obtain an exposure image.

[0104] Immunohistochemical staining:

[0105] A. Soak the tissue sections in xylene I-III in sequence for full dewaxing, then soak them in anhydrous ethanol I-III and 95% ethanol in sequence for hydration, and wash with distilled water.

[0106] B. The slices were placed in 3% hydrogen peroxide solution, incubated at room temperature in the dark, rinsed with distilled water and allowed to stand.

[0107] C. Place the slices in EDTA antigen retrieval buffer, the pH value of the antigen retrieval solution is 9.0, place the EDTA in the antigen retrieval buffer in a microwave oven, and heat it for antigen retrieval. Allow the heated slices to cool naturally, and then place them in PBS (PH7.4) and shake them repeatedly for washing.

[0108] D. Use a histochemical pen to draw a circle around the sliced ​​tissue, add 10% normal rabbit serum to cover the tissue, and incubate in an oven at 37°C for 30 minutes.

[0109] E. Gently shake off the blocking solution on the slices and add the primary antibody and incubate overnight at 4°C.

[0110] F. After washing the sections, add secondary antibody and incubate at room temperature for 30 minutes.

[0111] G. Wash the slices, add streptavidin-horseradish peroxidase, leave at room temperature for 20 minutes, wash, add 100 μl of freshly prepared DAB working solution (enough to cover the tissue), leave to observe until the reaction site turns yellow-brown, then wash.

[0112] H. Counterstain the sections with hematoxylin for about 3 minutes, differentiate with 1% hydrochloric acid alcohol, turn the sections blue, and rinse with running water.

[0113] I. The slices are passed through 75% alcohol and 85% alcohol in turn, then through anhydrous ethanol, and finally through xylene, the purpose of which is to fully dehydrate. The dehydrated slices are slightly air-dried and then sealed. The results are observed under a microscope.

[0114] The ascending aorta (AsAo or Asc) of control wild-type mice and Marfan syndrome model mice were subjected to WB protein immunoblotting and immunohistochemical staining, and the descending aorta (DeAo or Desc) and abdominal aorta (AbAo) were subjected to immunohistochemical staining.

[0115] The results of WB protein immunoblotting of mouse ascending aorta are as follows Figure 3 As shown, Figure 3 The results showed that the Piezo1 protein content in the ascending aorta of Marfan syndrome model mice was significantly lower (P = 0.0018) than that in the ascending aorta of wild-type mice; the results of immunohistochemical staining experiments of AsAo, DeAo, and AbAo in mice were as follows Figure 4 As shown, Figure 4 The results showed that the Piezo1 protein levels in the ascending aorta, descending aorta, and abdominal aorta of Marfan syndrome model mice were significantly lower than those in wild-type mice (P values ​​were 0.0005, 0.0001, and 0.0047, respectively). Both immunoblotting and immunohistochemistry experiments showed that Piezo1 molecules were abnormally downregulated in all segments of the aorta of MFS model mice.

[0116] Using the same experimental method as above, WB protein immunoblotting and immunohistochemical staining were performed on blood vessel samples of healthy subjects (Donor) and patients with Marfan syndrome (MFS). The experimental results are as follows: Figure 5 and Figure 6 As shown, the experimental results showed that the Piezo1 molecule was also abnormally downregulated in the vascular samples of MFS patients.

[0117] In order to further explore the effect of Piezo1 gene deletion on thoracic aortic aneurysm, Piezo1 gene knockout mice were constructed to study the role of Piezo1 molecules in Marfan syndrome aneurysm disease.

[0118] Example 3 Study on the role of Piezo1 gene in aneurysmal disease in Marfan syndrome

[0119] Construction of gene knockout mice: Using the principle of homologous recombination, the Piezo1 gene was floxed by homologous recombination of fertilized eggs, and then hybridized with Cre mice to obtain specific gene knockout mice. Figure 7 shown.

[0120] The experimental mice were divided into four groups: control group (CON), conditional knockout group (CKO), Marfan syndrome model group (MFS), and Marfan syndrome superimposed conditional knockout group (MFS x CKO). Ultrasound detection (VisualSonics, Inc., Australia) was performed according to the matching weeks of age. At 14 weeks of age, the aortic segments (ascending aorta, arch aorta, descending aorta) were dissected and sampled. The diameter of the aorta in each segment was measured and photographed. The anatomical diagram is shown in the figure. Figure 8 As shown in the figure above, ultrasound images are Figure 8 As shown in the figure below, the diameter of the aorta in each segment is plotted as a bar graph. Fig. 9 As shown, the experimental results showed that the Piezo1 gene was knocked out in the disease model mice, and after natural growth to 14 weeks of age, they exhibited severe thoracic aortic aneurysms, and the aortic dilatation was more severe and occurred earlier than their controls.

[0121] The CON, CKO, MFS, and MFS x CKO groups of mice were subjected to protein extraction, immunoblotting, and staining experiments, including HE staining, EVG staining, and immunofluorescence staining. Another part of the aorta was extracted for mRNA transcriptome sequencing (IlluminaNovaSeq 6000). GSEA enrichment analysis was performed in R language to draw signal pathway change images and gene expression heat maps.

[0122] Western blotting and bioinformatics analysis were the same as those described in Example 2 and Example 1. The main experimental methods and steps of HE staining, immunofluorescence staining and EVG staining are as follows.

[0123] HE staining: A. Put the slices into xylene I for 10 minutes; xylene II for 10 minutes; anhydrous ethanol I for 5 minutes; anhydrous ethanol II for 5 minutes; 95% alcohol for 5 minutes; 90% alcohol for 5 minutes; 80% alcohol for 5 minutes; 70% alcohol for 5 minutes and then wash with distilled water. B. Stain the slices with Harris hematoxylin for 3-8 minutes and wash with distilled water. C. Stain the slices with eosin stain for 1-3 minutes and wash with distilled water. D. Put the slices into 95% alcohol I for 5 minutes; 95% alcohol II for 5 minutes; anhydrous ethanol I for 5 minutes; anhydrous ethanol II for 5 minutes; xylene I for 5 minutes; xylene II for 5 minutes to dehydrate and make them transparent. Take the slices out of xylene and let them dry slightly, then seal them with neutral gum.

[0124] Immunofluorescence staining: A. Dewaxing, antigen repair, serum blocking, and primary antibody staining steps are the same as immunohistochemical staining. B. Rinse the sections 3 times, 3 minutes each time, wipe the sections dry with absorbent paper, add the diluted fluorescent secondary antibody, incubate in a wet box at 20-37 degrees Celsius for 1 hour, and wash the sections. C. Add DAPI (Seville) and incubate in the dark for 5 minutes, stain the specimens, and wash the sections.

[0125] EVG staining: A. Dewaxing procedures are the same as HE staining. B. Slices are stained in Verhoeff's staining solution for 15-30 minutes until the color turns dark black. C. Rinse with tap water, differentiate with 2% ferric chloride solution for 10-20 seconds, and observe under a microscope that the elastic fibers are black and the background is gray. D. Rinse with tap water, treat with 5% sodium thiosulfate for 1 minute to remove iodine. E. Restain with Van Gieson's solution for 3-5 minutes, and wash with anhydrous ethanol. F. Dehydration and sealing procedures are the same as HE staining.

[0126] HE staining, EVG staining pictures and corresponding elastic fiber breaks (Elastinbreaks) are shown as follows Fig.10 As shown, from Fig.10The pathological staining results and elastic fiber rupture showed that the Piezo1 gene deletion led to increased vascular wall thickness, disordered extracellular matrix, conversion of vascular smooth muscle cell phenotype from contractile to synthetic secretory, and aggravated thinning and rupture of elastic fibers (P=0.0291), further confirming the experimental results of aneurysm aggravation in the above experiment.

[0127] To further explore the changes in arterial blood vessels, the inventors conducted transcriptome sequencing, and the experimental results are as follows: Fig.11 and Fig.12 As shown, Fig.11 The results showed that Piezo1 gene deletion led to increased cell apoptosis and aggravated extracellular matrix remodeling. Fig.12 The gene expression heat map results showed that collagen and matrix metalloproteinase family were upregulated, which was consistent with the pathway enrichment results.

[0128] Page 14 of 30

[0129] MMP9 is a secreted member of the zinc metalloendopeptidase family. MMP9, also known as gelatinase B or 92kDa type IV collagenase (EC3.4.24.35), is one of the two gelatinases in the matrix metalloproteinase (MMP) family of zinc metalloendopeptidases. It is a multidomain protein with a molecular weight of 92kDa that catalyzes the degradation of large extracellular matrix (ECM) components such as elastin and collagen, as well as certain cell surface proteins. MMP2 is a matrix metalloproteinase that can degrade the extracellular matrix and is involved in a variety of physiological processes such as vascular remodeling, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.

[0130] In order to explore the effect of TGF-β signaling pathway on MFS, the inventors conducted immunofluorescence staining experiments on MMP2, MMP9, and p-SMAD2 proteins, and immunoblotting experiments on MMP2, MMP9, p-SMAD2, SMAD2, p-ERK1 / 2, and ERK1 / 2 proteins. The experimental results are as follows: Fig.13 and Fig.14 As shown, the experiment showed that compared with the control group, Piezo1 gene knockout would aggravate the abnormal activation of the TGF-β signaling pathway (increased phosphorylation of SMAD2 and ERK1 / 2), thereby causing the increased expression of the metal matrix proteinase family (MMP2, MMP9), destroying and remodeling the extracellular matrix, and aggravating aneurysms.

[0131] The above experimental results indicate that the Piezo1 molecule plays a protective role in the occurrence and development of aneurysms, and its downregulation will lead to the deterioration of the disease. Intervention of this molecule may be an effective measure to treat MFS aneurysms.

[0132] Example 4 Study on the effect and mechanism of Piezo1 agonist on TGF-β signaling pathway

[0133] MFS model mice were dissected, aorta vessels were taken, and primary cells were extracted for in vitro culture. The culture conditions were: DMEM + 20% fetal bovine serum medium and 37°C constant temperature carbon dioxide cell culture incubator. 10mM Yoda1 (HY-18723, MedChemExpress) and 10ng / ml TGF-β1 (781802, Biolegend) were given for stimulation for 24 hours. Cell samples were collected, and total cell protein, cell membrane protein and cell mRNA were extracted respectively. Total protein was detected by immunoblotting and immunofluorescence staining to observe the change level of TGF-β signaling pathway related indicators. Cell membrane protein was detected by immunoblotting and immunofluorescence to observe the changes of TGF-β signaling pathway receptors 1 and 2 in the cell membrane and cytoplasm. Cell mRNA was sequenced by transcriptome sequencing, and GSEA and GSVA enrichment analysis were used in R language to draw signal pathway change pictures and gene expression heat maps.

[0134] FN1 is a multifunctional extracellular matrix protein and a high molecular weight glycoprotein. It can bind to multiple components on the cell surface and in the extracellular matrix, including collagen, fibrin, heparin, DNA, and actin. COL1A1 is a collagen protein, which is a major component of the extracellular matrix and can promote cell adhesion and migration.

[0135] MFS smooth muscle cells (VSMCs) were treated in vitro with the Piezo1 molecule-specific agonist Yoda1, and immunoblotting was performed using the method described in the above example. The immunoblotting images are shown in FIG. Fig.15 shown.

[0136] In the case of adding or not adding Yoda1, 10mYoda1 (HY-18723, MedChemExpress) and 10ng / ml TGF-β1 (781802, Biolegend) were co-stimulated for 24 hours or 10ng / ml TGF-β1 (781802, Biolegend) was stimulated alone for 24 hours, and p-SMAD2 and p-ERK1 / 2 protein immunofluorescence staining experiments were performed.

[0137] Color pictures such as Fig.16 shown.

[0138] Fig.15 and Fig.16 The experimental results showed that after Yoda1 treated smooth muscle cells in vitro, Yoda1 reduced the indicators of extracellular matrix proteins (such as Fig.15Left: After Yoda1 treatment, the levels of FN1, COL1A1, MMP2, and MMP9 decreased, and the activation of the TGF-β signaling pathway was inhibited (Fig. Fig.15 Right panel, after adding Yoda1, the phosphorylation of SMAD2 and ERK1 / 2 decreased; Fig.16 , the fluorescence of the TGF-β+Yoda1 group was reduced), and the expression of collagen and matrix metalloproteinase-related proteins was decreased, indicating that Yoda1 may be used as a therapeutic agent for MFS aneurysms.

[0139] In order to further explore the molecular mechanism of Yoda1 acting on MFS aneurysms, the inventors divided the cell samples into groups and performed transcriptome sequencing. The image of the signal pathway changes is shown in Figure 2. Fig.17 As shown in the heat map of gene expression Fig.18 The experimental results showed that after Yoda1 stimulation, extracellular matrix remodeling, angiotensin pathway, apoptosis pathway and other pathways were all decreased, indicating that Yoda1 inhibited the development of aneurysms, lowered blood pressure, and protected against smooth muscle apoptosis.

[0140] The inventors further performed protein immunoblotting on the receptors (TGFBR1 and TGFBR2) of the TGF-β signaling pathway on the cell membrane. Fig.19 As shown in the results, it was found that after Yoda1 treatment, the content of TGFBR1 receptor in the cell membrane and cytoplasm did not change, while the content of TGFBR2 receptor in the cell membrane decreased and the content in the cytoplasm increased. The experimental results showed that the expression of TGFBR1 receptor did not change under Yoda1 stimulation, while the expression of TGFBR2 receptor decreased under Yoda1 stimulation and increased in the cytoplasm. At the same time, immunofluorescence confocal microscopy captured the transfer process of TGFBR2 receptor from the cell membrane to the cytoplasm (such as Fig. 20 ). The reduced expression of TGFBR2 receptor on the cell membrane leads to the inhibition of activation of TGF-β signaling pathway.

[0141] Example 5 Study on the effect of injection of Piezo1 agonist drug (Yoda1) in mice with Marfan syndrome aneurysm model

[0142] The experimental groups were wild-type mice (WT), MFS model mice (MFS+Vehicle), and MFS model mice injected with Yoda1 intraperitoneally (MFS+Yoda1). Yoda1 (10 μM / kg) was injected intraperitoneally into MFS model mice from 4 to 24 weeks of age, and WT, MFS+Vehicle, and MFS+Yoda1 mice were dissected, and the aortic segments were taken for photographs and ultrasound detection.

[0143] Main experimental methods and steps of ultrasonic testing:

[0144] Ultrasound of mouse aorta: A. Echocardiograms were obtained using a Vevo 1100 ultrasound system (visualsonic). B. Mice were anesthetized with 2% isoflurane, chest hair was removed, and the temperature was maintained at 37°C on a platform. C. The diameters of the ascending aorta, arch aorta, descending aorta, and abdominal aorta were assessed by parasternal long-axis B and M modes, measuring from the inner edge to the inner edge of the other side at the end of diastole. Three measurements were averaged for each mouse.

[0145] Anatomy and ultrasound examination pictures Fig.21 As shown in Figure 2, the diameter detection results of the ascending aorta (Asc), arch aorta (Arch), and descending aorta (Desc) are as follows: Fig. 22 shown.

[0146] The relevant proteins of each group of mice were subjected to HE staining, EVG staining, immunofluorescence staining and immunoblotting detection using the same methods as in the above examples.

[0147] HE staining and EVG staining pictures and the corresponding elastic fiber breaks (Elastin breaks) are shown below Fig.23 As shown, Fig.23 The results showed that the vascular wall thickness of mice in the MFS+Yoda1 group was reduced and the elastic fiber rupture was weakened compared with that in the MFS+Vehicle group.

[0148] Immunofluorescence staining images of MMP2, COL1A1, p-SMAD2, and p-ERK1 / 2 proteins and the percentage of the positive areas of the corresponding proteins are shown in Fig.24 As shown, Fig.24 The results showed that the expression of MMP2, COL1A1, p-SMAD2, and p-ERK1 / 2 proteins in the MFS+Yoda1 group of mice was significantly lower than that in the MFS+Vehicle group of mice.

[0149] MMP2, MMP9, p-SMAD2, SMAD2, p-ERK1 / 2, ERK1 / 2 protein immunoblotting detection pictures are as follows Fig.25 As shown, Fig.25 The results showed that the phosphorylation of TGF-β signaling pathway markers SMAD2 and ERK1 / 2, and the expression of extracellular matrix-related proteins (MMP2 and MMP9) in the MFS+Yoda1 group mice was reduced compared with that in the MFS+Vehicle group mice.

[0150] from Figure 21-23 It can be seen that Yoda1 injection reduced the vascular dilation of MFS aneurysms, and pathological staining showed that the thickness of the vascular wall was reduced, the extracellular matrix remodeling was reduced, and the elastic fiber rupture was weakened.

[0151] from Figure 24-25 It can be seen that the activation of TGF-β signaling pathway (p-ERK1 / 2, p-SMAD2) and proteins related to extracellular matrix remodeling (MMP2, MMP9) were reduced, indicating that the expansion of MFS aneurysms was inhibited.

[0152] SQSTM1 protein (Sequestosome1, P62) is a multifunctional scaffold protein that participates in the regulation of multiple signaling pathways and autophagy. P62 is an essential adaptor for an important autophagy receptor protein. Its UBA domain recognizes and binds ubiquitinated proteins, interacts with autophagy proteins to target autophagosomes, and is effectively degraded by autolysosomes as an indicator of autophagic degradation (Zheng Ronghui, Li Pan, Cao Xiuqin, He Ruixia, Chen Minjia, Chen Haixia, Yang Zhiwei. Mechanism of action of SQSTM1 protein in autophagy of RAW264.7 cells infected with Legionella pneumophila [J]. Journal of Shandong University (Medical Edition), 2023, 61(6): 10-21.).

[0153] LC3 is a marker of autophagy. When autophagy occurs, the cytoplasmic LC3 (i.e., LC3-I) will enzymatically hydrolyze a small segment of the polypeptide and transform into the autophagosome membrane type (i.e., LC3-II). The size of the LC3-II / I ratio can estimate the level of autophagy.

[0154] The inventors simultaneously performed immunoblotting and immunohistochemical staining experiments on autophagy-related proteins (SQSTM1, LC3-I, LC3-II), and also performed immunoblotting on the TGF-β receptor TGFBR2 protein in the cell membrane, using β-actin as the internal reference protein.

[0155] The results of immunoblotting of SQSTM1, LC3-I, and LC3-II proteins are shown in Fig.26 The results of immunoblotting of TGFBR2 protein are shown in Fig. 27 The immunohistochemical staining results of SQSTM1 protein are shown in Fig.28 As shown, Fig.28 The left picture is an immunohistochemical staining photo. Fig.28 The right figure is a bar graph showing the percentage of SQSTM1 protein staining area. Figure 26-28 It can be seen that the degree of vascular autophagy in the MFS+Yoda1 group mice was increased compared with that in the MFS+Vehicle group mice, and compared with the wild-type WT mice.

[0156] That is to say, Yoda1 increases the degree of vascular autophagy and improves aneurysm expansion. The Piezo1 agonist Yoda1 can be used as a reagent drug for the treatment of Marfan syndrome aneurysms.

[0157] According to prior art reports, Jedi2 and Yaddle1, like Yoda1, can enhance Ca 2+ influx; co-administration of Jedi1 and Yoda1 produces a synergistic activation effect on Piezo1, indicating that these two agonists may activate Piezo1 through different binding sites. Jedi1, Jedi2, and Yaddle1 are all Piezo1 agonists, which can increase the activity of Piezo1 protein or upregulate the expression level of Piezo1 gene, further inhibiting the TGF-β signaling pathway, and the inhibition of the TGF-β signaling pathway is achieved by inhibiting the expression of TGFBR2 protein on the cell membrane or by transferring TGFBR2 protein from the cell membrane to the cytoplasm. Therefore, those skilled in the art can expect that Jedi1, Jedi2 or Yaddle1 may show the same pharmacological effect of treating Marfan syndrome aneurysms as Yoda1.

[0158] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of this application should be included in the protection scope of this application.

Claims

1. Use of a Piezo1 agonist or a pharmaceutically acceptable salt or ester thereof in the preparation of a medicament for treating Marfan syndrome.

2. Use of Piezo1 gene or protein in the preparation of drugs for treating Marfan syndrome.

3. The use according to claim 1, wherein The Piezo1 agonist is selected from substances that can increase the activity of Piezo1 protein or upregulate the expression level of Piezo1 gene. Preferably, the Piezo1 agonist is selected from Yoda1, Jedi1, Jedi2 or Yaddle1.

4. The use according to claim 1 or 2, wherein The Marfan syndrome is manifested as a thoracic aortic aneurysm, which is manifested as an aneurysmal dilatation of the aortic root or ascending aorta.

5. The use according to claim 1 or 2, wherein The drug for treating Marfan syndrome can be achieved by inhibiting the TGF-β signaling pathway.

6. The use according to claim 5, wherein The inhibition of the TGF-β signaling pathway can be achieved by inhibiting the expression of TGFBR2 protein on the cell membrane or transferring the TGFBR2 protein from the cell membrane to the cytoplasm.

7. A pharmaceutical composition for treating Marfan syndrome, characterized in that: The pharmaceutical composition contains at least one of a Piezo1 agonist, a Piezo1 protein or a TGF-β inhibitor.

8. The pharmaceutical composition according to claim 7, wherein The Piezo1 agonist is selected from substances that can increase the activity of the Piezo1 protein or upregulate the expression level of the Piezo1 gene.

9. The pharmaceutical composition according to claim 7, wherein The Piezo1 agonist is selected from Yoda 1, Jedi1, Jedi2 or Yaddle1.

10. The pharmaceutical composition according to claim 7, wherein The Marfan syndrome is manifested as a thoracic aortic aneurysm, which is manifested as an aneurysmal dilatation of the aortic root or ascending aorta.